Volition Nu.Q® Vet Commercial Strategy Webinar


Volition Nu.Q® Vet Commercial Strategy Webinar

VolitionRx Limited (NYSE AMERICAN: VNRX) (‘Volition’), a multinational epigenetics company, is taking part in a webinar hosted by Edison Group, which will focus on Volition’s Nu.Q® Vet commercial strategy.

The webinar takes place on Thursday, January 26 at 12 noon US Eastern Time and will include updates from Dr Tom Butera (Chief Executive Officer), Dr Heather Wilson- Robles (Chief Medical Officer) of Volition Veterinary Diagnostics Development LLC, and Gael Forterre, Volition’s Chief Commercial Officer.

The panel and Q&A event is being hosted by Soo Romanoff, Managing Director of Healthcare at Edison Group. It follows the release of ‘Vetting the pet health opportunity’, an insights report on Volition.

Event Details:

Title: Nu.Q® Vet Commercial Strategy

Date: Thursday, January 26, 2023

Time: 12 noon Eastern, US

Register at: https://edisongroup.zoom.us/webinar/register/WN_TjeTdVOLQry4PpBJyzLCpg

Dr Tom Butera, Chief Executive Officer of Volition Veterinary Diagnostics Development LLC, said: “The Nu.Q® Vet Cancer Test is a simple, cost-effective, easy-to-use blood test for screening older or ‘at risk’ dogs. It was developed with the goal of providing an accessible and affordable screening test to aid early detection.

“We are now embarking on a pivotal phase for Volition as we continue to roll out our Nu.Q® technology within the companion animal healthcare sector and capitalize on what we believe to be significant mass market opportunities. It is a hugely exciting time for the company.”

To register for the Nu.Q® Vet Commercial Strategy webinar click HERE. The event will be recorded and available afterwards on demand.

Volition is developing simple, easy-to-use, cost-effective blood tests to help diagnose and monitor a range of life-altering diseases including cancer in both humans and animals. For more information about Volition’s Nu.Q® technology go to: www.volition.com.

About Volition
Volition is a multinational epigenetics company that applies its Nucleosomics™ platform through its subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor a range of life-altering diseases, in both humans and other animals, including some cancers and diseases associated with NETosis such as sepsis and COVID-19. Early diagnosis and monitoring have the potential not only to prolong the life of patients but also to improve their quality of life. The tests are based on the science of Nucleosomics™, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid – an indication that disease is present.

Volition’s research and development activities are centered in Belgium, with an innovation laboratory and office in the US and additional offices in London and Singapore.

The contents found at Volition’s website address are not incorporated by reference into this document and should not be considered part of this document. This website address is included in this document as an inactive textual reference only.


Related Research

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free